Polifarmasi merupakan penggunaan bersamaan enam obat atau lebih oleh seorang pasien. Semakin banyak obat yang digunakan maka semakin tinggi potensi interaksi yang terjadi dan dapat menyebabkan efek samping yang berbahaya. Tujuan dari penelitian ini adalah mengetahui resiko efek samping dan potensi interaksi obat pada resep polifarmasi nonracikan. Identifikasi terkait potensi efek samping dan interaksi obat dinilai berdasarkan database dari Medscape Drug Interaction Checker, RxList Drug Interaction Checker, drugs.com Drug Interaction Checker, dan WebMD Drug Interaction Checker. Pada resep polifarmasi nonracik pertama ditemukan potensi efek samping berupa ketidakseimbangan elektrolit, hipotensi, hiperurisemia, asam urat, sakit kepala, dan mual/muntah serta terdapat dua potensi interaksi major dan empat potensi interaksi moderate. Sementara pada resep polifarmasi nonracik kedua ditemukan potensi efek samping berupa pencernaan yang terganggu, mengantuk, tremor otot rangka, peningkatan BUN atau kreatinin, dan bronkospasme serta terdapat lima potensi interaksi moderate. Berdasarkan mekansimenya, mayoritas potensi interaksi obat yang ditemukan adalah interaksi farmakodinamik (45.4%). Sementara berdasarkan tingkatannya, mayoritas potensi interaksi obat yang ditemukan adalah interaksi moderate (81.8%).

---

Polypharmacy is the concomitant use of six or more drugs by a patient. The more drugs used, the higher the potential for interactions that occur and can cause dangerous side effects. The purpose of this study was to determine the risk of side effects and potential drug interactions in nonconcocted polypharmacy prescriptions. Identification of potential side effects and drug interactions is assessed based on databases from Medscape Drug Interaction Checker, RxList Drug Interaction Checker, drugs.com Drug Interaction Checker, and WebMD Drug Interaction Checker. In the first non-mixed polypharmacy prescription, potential side effects were found in the form of electrolyte imbalance, hypotension, hyperuricemia, gout, headache, nausea, and vomiting, and there were two potential major interactions and four potential moderate interactions. While the second non-mixed polypharmaceutical prescription found potential side effects in the form of disturbed digestion, drowsiness, skeletal muscle tremors, increased BUN or creatinine, and bronchospasm, there were five potential moderate interactions. Based on the mechanism, the majority of potential drug interactions found were pharmacodynamic interactions (45.4%). Based on the level, the majority of potential drug interactions found were moderate (81.8%).